1. New Patient Journeys in Non-small cell lung cancer

3. Program Overview

4. Case #1: Immunotherapy in EGFR Mutation-Negative NSCLC

5. Testing for PD-L1 Expression: KEYNOTE-024

6. KEYNOTE-024: Results

7. Testing for PD-L1 Expression in the Clinic

8. Immune-Related AEs

9. Immune-Related Pneumonitis vs EGFR TKI-Associated ILD

10. Defining the Optimal Duration of Anti-PD-1/PD-L1 Therapy

11. KEYNOTE-010: Outcomes After 2 Years of Treatment

12. Determining the Optimal Treatment Schedule for Anti-PD-1/PD-L1 Therapy

13. Determining the Optimal Treatment Dose of Pembrolizumab

14. Case #2: Immunotherapy After EGFR TKI

15. Considerations in Using Immunotherapy in Previously Treated Patients

16. Second-line Nivolumab: CHECKMATE-057

17. Atezolizumab in Previously Treated NSCLC: OAK

18. Atezolizumab in Previously Treated NSCLC: OAK (cont)

19. Immunotherapy in Patients With EGFR Mutations

20. PD-L1 Expression in EGFR Mutation Positive Patients

21. PD-L1 Expression in EGFR Mutation Positive Patients (cont)

22. Immunotherapy in Patients With Brain Metastases

23. Pembrolizumab in Brain Metastatic NSCLC

24. Osimertinib in T790M-Mutant Brain Metastatic Disease

25. Osimertinib in EGFR-Mutant NSCLC and Leptomeningeal Disease

26. Combining Osimertinib and Immunotherapy

27. Conclusions

28. Abbreviations

29. Abbreviations (cont)